Telmisartan for the reduction of cardiovascular morbidity and mortality

References

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med.3, e442 (2006).
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernández R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged EU. Eur. Heart J.27, 1610–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart Disease and Stroke Statistics – 2010 Update. A report from the American Heart Association. Circulation121, e46–e215 (2009).
   PubMedGoogle Scholar
• Unger T. The role of the renin–angiotensin system in the development of cardiovascular disease. Am. J. Cardiol.89(Suppl.), 3A–10A (2002).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin–angiotensin system and cardiovascular risk. Lancet369, 1208–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The HOPE Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest129(Suppl. 1), 1695–1735 (2006).
   Google Scholar
• Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillenfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension51, 1624–1630 (2008).
   PubMed Web of Science ®Google Scholar
• Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension51, 1465–1367 (2008).
   PubMed Web of Science ®Google Scholar
• Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney and more. Trends Cardiovasc. Med.1, 30–34 (2007).
   Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al.; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J; OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet360, 752–760 (2002).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CP et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet362, 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson P, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet355, 1582–1587 (2000).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin–angiotensin system. Am. J. Hypertens.21, 852–859 (2008).
   PubMed Web of Science ®Google Scholar
• Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J. Int. Med. Res.37, 1662–1679 (2009).
   PubMed Web of Science ®Google Scholar
• Wienen W, Entzeroth M, van Meel JCA et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc. Drug Rev.18, 127–154 (2000).
   Google Scholar
• Maillard MP, Perregaux C, Centeno C et al.In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther.302, 1089–1095 (2002).
   PubMed Web of Science ®Google Scholar
• Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res.25, 41–46 (2005).
   PubMedGoogle Scholar
• Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ -modulating activity. Hypertension43, 993–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res.28, 149–167 (2000).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J. Hum. Hypertens.23, 610–619 (2009).
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Türck D et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J. Clin. Pharmacol.40, 1312–1322 (2000).
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens.14(Suppl. 1), S73–S86 (2000).
   PubMed Web of Science ®Google Scholar
• Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos.27, 1143–1149 (1999).
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Anderson C et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. (ONTARGET/TRANSCEND) trials. Am. Heart J.148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C et al.; Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet372, 1174–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL et al.; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359, 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Sleight P, Mancia G et al; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation120, 1380–1389 (2009).
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int.74, 364–369 (2008).
   PubMed Web of Science ®Google Scholar
• Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with Type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant.23, 3174–3183 (2008).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Bain SC, Bouter P et al; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med.351, 1952–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372, 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Krzesinski J-M, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit.9, 203–210 (2004).
   PubMed Web of Science ®Google Scholar
• Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can. J. Cardiol.16, 1123–1132 (2000).
   PubMed Web of Science ®Google Scholar
• Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J. Hypertens.22, 837–846 (2004).
   PubMed Web of Science ®Google Scholar
• Xi GL, Cheng JW, Lu GC Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am. J. Hypertens.21, 546–552 (2008).
   PubMed Web of Science ®Google Scholar
• Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press.17(Suppl. 1), 32–40 (2008).
   Web of Science ®Google Scholar
• Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension. An open-label observational study. Drug Saf.27, 335–344 (2004).
   PubMed Web of Science ®Google Scholar
• Zou Z, Xi G-l, Yuan H-B, Zhu Q-F, Shi X-Y. Telmisartan versus angiotensin-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomised controlled trials. J. Hum. Hypertens.2395, 339–349 (2009).
   Google Scholar
• Littlejohn TW 3rd, Majul CR, Olvera R et al.; Study Investigators. Results of treatment with telmisartan–amlodipine in hypertensive patients. J. Clin. Hypertens. (Greenwich)11, 207–213 (2009).
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens.26, 819–824 (2008).
   PubMed Web of Science ®Google Scholar
• Costa FV, Esposti LD, Cerra C, Veronesi C, Buda S. Trends in prescription and determinants of persistence to antihypertensive therapy. High Blood Press. Cardiovasc. Prev.16, 1–10 (2009).
   Google Scholar
• ESC/ESH. Mancia G, De Backer G, Dominiczak A et al.; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J.28, 1462–1536 (2007).
   PubMed Web of Science ®Google Scholar